GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Fisher & Paykel Healthcare Corp Ltd (NZSE:FPH) » Definitions » Cost of Goods Sold

Fisher & Paykel Healthcare (NZSE:FPH) Cost of Goods Sold : NZ$683 Mil (TTM As of Sep. 2023)


View and export this data going back to 1979. Start your Free Trial

What is Fisher & Paykel Healthcare Cost of Goods Sold?

Fisher & Paykel Healthcare's cost of goods sold for the six months ended in Sep. 2023 was NZ$318 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Sep. 2023 was NZ$683 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Fisher & Paykel Healthcare's Gross Margin % for the six months ended in Sep. 2023 was 61.07%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Fisher & Paykel Healthcare's Inventory Turnover for the six months ended in Sep. 2023 was 0.88.


Fisher & Paykel Healthcare Cost of Goods Sold Historical Data

The historical data trend for Fisher & Paykel Healthcare's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fisher & Paykel Healthcare Cost of Goods Sold Chart

Fisher & Paykel Healthcare Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 354.60 427.90 725.60 629.00 642.70

Fisher & Paykel Healthcare Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 332.30 296.70 277.40 365.30 317.60

Fisher & Paykel Healthcare Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NZ$683 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fisher & Paykel Healthcare  (NZSE:FPH) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Fisher & Paykel Healthcare's Gross Margin % for the six months ended in Sep. 2023 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(815.8 - 317.6) / 815.8
=61.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Fisher & Paykel Healthcare's Inventory Turnover for the six months ended in Sep. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Fisher & Paykel Healthcare Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Fisher & Paykel Healthcare's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Fisher & Paykel Healthcare (NZSE:FPH) Business Description

Traded in Other Exchanges
Address
15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use humidifiers, masks and related consumables and the number three player in the at-home treatment of sleep apnoea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns 42% of its revenue in the U.S., 32% in Europe, 18% in Asia-Pacific and the remaining 8% in emerging markets. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand and Mexico and has a multichannel distribution model.